

Quality Improvement Guidelines for Endovascular Treatment of Iliac Artery Occlusive Disease

Dimitrios Tsetis · Raman Uberoi

Published online: 22 November 2007
© Springer Science+Business Media, LLC 2007

Abstract Endovascular therapy is the treatment of choice for type A and the preferred treatment for type B lesions. In selective patients, this type of treatment can be applied in type C and even type D lesions. Ipsilateral femoral, contralateral femoral, and brachial approach and both the intraluminal and subintimal space can be used for successful recanalization. The application of stents has improved the immediate hemodynamic and probably long-term clinical results of iliac percutaneous transluminal angioplasty. However, the superiority of primary or direct stenting over selective stenting has not been proven yet. The choice of stent type depends on lesion morphology and location but otherwise there is insufficient evidence to support the use of a particular stent design. There is insufficient evidence to justify routine use of covered stents. All patients should receive antiaggregant therapy following endovascular recanalization of iliac arteries. There is no consensus regarding prophylaxis with antibiotics in iliac recanalization procedures

Keywords Iliac artery · Occlusive disease · Angioplasty · Stenting · Thrombolysis · Endovascular treatment

The annual incidence of symptomatic peripheral arterial obstructive disease (PAOD) is 26/10,000 in men and

12/10,000 in women according to the results of the Framingham study; this means that PAOD is at least as frequent as angina in the U.S. population [1]. Using noninvasive testing the prevalence of the disease is estimated to be 3% in middle-aged patients, increasing to 20% in patients >70 years of age [2, 3]. About one-third of PAOD lesions in the body affect the aorto-iliac segment.

The most common clinical manifestation of PAOD is intermittent claudication involving the upper thigh, often in combination with lower limb claudication. Patients presenting with critical limb ischemia usually have multisegmental disease with involvement of the infra-inguinal arteries. Erectile dysfunction may also be present in males. Occasionally ulcerated iliac plaques can result in cholesterol or thrombotic embolization leading to blue toe syndrome.

On clinical examination patients often have weakened femoral pulses and a reduced ankle/brachial index. Verification of iliac occlusive disease is usually made by color duplex scanning which reveals either a peak systolic velocity ratio ≥ 2.5 at the site of stenosis and or a monophasic waveform. Magnetic resonance angiography (MRA) and multiple detector-row computed tomography angiography (MDCTA) are increasingly used for determining the extent and type of obstruction, however, digital subtraction angiography (DSA) offers the unique advantage of incorporating diagnostic confirmation and endovascular treatment in a single session.

Patient Selection

According to the recently updated TransAtlantic Consensus Document on treatment of PAOD (TASC II), the choice between endovascular therapy and surgery depends on the lesion type in terms of complexity and length [4].

D. Tsetis (✉)
Department of Radiology, University Hospital of Heraklion,
Medical School of Crete, P.O. Box 1352, Stavrakia 71110,
Heraklion, Crete, Greece
e-mail: tsetis@med.uoc.gr

R. Uberoi
Department of Radiology, The John Radcliffe Hospital,
Oxford, UK

Indications

Pelvic and lower limb ischemia: claudication <200 m, limb-threatening ischemia, blue toe syndrome, renal transplantation, and vasculogenic impotence (TASC A and B).

Contra-Indications

Related to any percutaneous intervention (groin sepsis, bleeding diathesis, or severe coagulopathy) and TASC D.

Relative Contra-Indications

Anticoagulation, contrast allergy (CO₂ or gadolinium can be used as alternative contrast), and TASC C.

Technique

Endovascular interventions are routinely performed with the patient under local anesthesia supplemented by intravenous sedation and analgesia when indicated (i.e., prolonged procedures as well as in anxious or confused patients). Monitoring is recommended (pulse, blood pressure, ECG and oxygen saturation) in all patients, particularly when sedated.

The most commonly used vascular access for aorto-iliac revascularization is retrograde common femoral artery (CFA) access. Contralateral femoral, ipsilateral popliteal, or brachial/axillary access has been used. However, a combination of approaches may be necessary in order to recanalize complex lesions.

In difficult punctures ultrasound guidance and/or imaging (i.e., “roadmap” type) software commonly available on modern angiographic equipment can be invaluable in guiding arterial access. A sheath is routinely placed; the size, length, and configuration will be determined by the size of devices used, lesion position, approach, and anatomy (i.e., Balkin-type sheath for a contralateral approach).

A stenosis is normally crossed from an ipsilateral approach with a combination of a soft-tip 0.035-in guidewire (i.e., Bentson type wire) or hydrophilic wire and a 5-Fr straight or selective catheter (i.e., Cobra type).

Both common iliac artery (CIA) and external iliac artery (EIA) total occlusions are negotiated first from an ipsilateral approach. If this approach fails, then a curved catheter (i.e., 5-Fr Sos-Omni, 5- to 7-Fr renal curved or Simmons 1) is inserted from the contralateral femoral artery, and the occlusion is transversed with a hydrophilic 0.035-in. guide wire. If the wires from both directions end up subintimally in the occluded segment, the wire from the contralateral side is snared and pulled through the sheath in the ipsilateral groin [5]. A limitation of subintimal recanalization

is occasional true lumen re-entry remote from the level of vessel lumen patency, causing percutaneous transluminal angioplasty (PTA), stenting, or both to extend beyond the occluded segment. To overcome this technical challenge, catheters allowing passage of a needle and guide wire across the intima distal to the occlusion (i.e., the Pioneer and the Outback catheter) have been developed with promising initial results [6].

An alternative technique has been described in cases where re-entry into the true lumen cannot be achieved with the use of standard guide wires and catheters, when the subintimal space is entered from an ipsilateral approach; an 18-gauge sharp needle (i.e., Colapinto needle) is used to cross the space and indent an occlusion balloon inserted from the contralateral side, indicating proper orientation toward the true lumen of the aorta [7].

When the lesion is successfully crossed, balloons of an appropriate size and length are used (i.e., 8–10 mm for CIA, 6–8 mm for EIA). These are sized to the patient’s native vessel wherever possible. Inflation is performed with caution, especially in heavily calcified lesions, initially applying pressure of 8 atm for up to 60 s. However, higher pressures may be necessary for lesions where there is persistent waisting of the balloon.

Catheter-Directed Thrombolysis (CDT)

If guide-wire traversal appears relatively straightforward, the presence of a soft thrombus is likely and CDT may prove beneficial [8, 9]. However, other investigators have concluded that routine thrombolysis and balloon dilation of occluded arteries prior to stent placement are associated with an increased incidence of distal embolic events [10, 11]. If guide-wire traversal is challenging, it is unlikely that there is any benefit of CDT [12, 13].

Although percutaneous mechanical thrombectomy devices (i.e., Straub-Rotarex catheter) are now widely available, there are no convincing data on improved outcome in patients with chronic iliac artery occlusions. In addition, due to their relatively large caliber, hemolysis, complexity of manipulations, potential risks of downstream or crossover embolization, and elevated cost, they are not currently recommended for routine use [14, 15].

Indications for Stenting and Stent Selection

Accepted indications for iliac stent placement are failed or inadequate PTA as a result of elastic recoil and the presence of a flow-limiting dissection. Significant residual stenosis after balloon angioplasty is defined as residual stenosis >30% on angiography and/or a residual peak-to-peak systolic pressure gradient of >5 mm Hg [16, 17]. Primary (stent placement after predilation of the lesion regardless of the

PTA outcome) or direct (stent placement without predilation of the lesion) stenting is generally accepted in clinical practice for patients with chronic iliac artery occlusions and with recurrent stenosis after previous iliac PTA, though there is still little evidence to support the latter approach. Many interventionists find it intuitive to apply primary or direct stenting along complex stenoses (eccentric, calcified, ulcerated plaques, or plaques with spontaneous dissection) which are prone to cause distal embolization [18]. The efficacy of this practice has not been proven.

The choice of the appropriate stent type depends on the lesion morphology and location. When dealing with lesions of high elastic recoil, such as calcified or eccentric plaques at the ostium of the CIA or EIA, a balloon-expanded stent would be more appropriate than a self-expanding stent, because of its greater hoop strength [19, 20]. A self-expanding stent should be chosen to stabilize longer, less calcified vessel segments. In tortuous vessels, the application of stainless-steel balloon-expanded stents is not recommended, due to the risk of angulation or kinking of the vessel at the end of the stent [20]. Self-expanding stents (i.e., Nitinol stents, Wallstent) should be used instead, assuring good flexibility and vessel conformability when employed. Nitinol stents (especially those which are laser-cut from a single Nitinol tube) also seem appropriate for treating vascular segments that transit abruptly in size (e.g., from a CIA to an EIA 2 mm smaller in lumen size) [20].

Covered Stents

Covered stents are generally reserved for the treatment of isolated iliac aneurysms, iatrogenic perforation/ruptures, and arteriovenous fistulas. There have been limited studies in patients with PAOD. These devices are stainless-steel, nickel-cobalt-titanium-steel alloy (Elgiloy), or Nitinol stents covered with Dacron or polytetrafluoroethylene (PTFE) [21–23]. In theory covered stents should reduce in-stent restenosis by excluding the diseased segment from the circulation, however, experimental data suggest that they induce more neointimal overgrowth compared to bare stents [21]. Early clinical reports show that the insertion of stent-grafts combined with CFA endarterectomy may offer superior long-term patency in diffuse aorto-iliac occlusive disease (TASC C and D lesions) compared with bare stents [22]. Despite the encouraging early results, more studies are needed in order to justify the routine use of such devices in aorto-iliac occlusive disease.

Anticoagulation/Antiaggregant Therapy

The majority of operators give 5000 IU of heparin intrarterially at the time of the procedure. Full heparinization (500–1000 IU/h) can be continued for 12 to 24 h—

particularly in difficult cases—to increase the activated partial thromboplastin time to two or three times normal [24]; alternatively, low-dose, low molecular weight heparin therapy is administered until hospital discharge [25, 26]. All patients should receive antiaggregant therapy, usually aspirin (100–325 mg/day), on a lifetime basis, alone [24, 25, 27] or in combination with clopidogrel [26, 28], although there is no evidence of improved outcome with the addition of clopidogrel to this regime.

Follow-up

Follow-up comprises the following: history and clinical examination, ankle-brachial index (ABI) measurement, and proof of patency, i.e., duplex ultrasonography, angiography, CTA, or MRA. Definitions of immediate technical and clinical success, clinical success during follow-up, and patency are given in Appendix II.

Direct visualization with angiography is still considered by many to be the gold standard, however, duplex, CTA, and MRA now give a more acceptable noninvasive option. Duplex can be difficult in large patients and in the presence of heavy calcification, however, these can usually be overcome in the vast majority of patients [29]. CTA can overestimate the degree of in-stent stenosis, while heavy calcification can limit the diagnostic accuracy of the method by causing a “blooming artifact” [30]. MRA is contraindicated in some patients such as those with defibrillators, spinal cord stimulators, intracerebral shunts, cochlear implants, and cranial clips. The negative influence of metallic stents on image quality in contrast-enhanced depends on the stent architecture and material, with Nitinol stents producing minimal artifact [31]. Allowing for these limitations, direct imaging postintervention is feasible in the vast majority of patients. Currently there are no standardized protocols for imaging and surveillance postendovascular intervention, however, it seems reasonable to carry out imaging to document outcome at 6 and 12 months postprocedure.

Treatment of Restenosis

The currently accepted method for treating iliac in-stent restenosis, due to either intimal hyperplasia or disease progression following PTA/stenting, is repeated balloon dilation and/ or implantation of a second stent [32]. Repeat stent placement (resulting in a “stent sandwich”) may show excellent short-term technical success, however, it bears the disadvantage of consequent arterial wall overexpansion, with the potential of the induction of further neointimal response [33]. There is no proof at present that

stent placement in a restenosed vessel is beneficial to prevent future stenosis. Directional atherectomy appears to be a useful method by debulking the stent of its neointimal tissue prior to the upcoming balloon dilation or further stent placement [34]. Atheroablation techniques in general have not been widely accepted on the grounds of additional cost and skill demand [35]. Cutting balloon angioplasty offers an attractive therapeutic alternative for the treatment of iliac in-stent restenosis [36], however, adequate scientific evidence is still lacking.

Outcome

The reported technical and initial clinical success of balloon angioplasty in iliac artery stenoses exceeds 90% in most series and the 5-year patency rates range between 54% and 92% (Table 1). Becker et al. estimated a 5-year patency rate of 72% in an analysis of 2697 cases of iliac angioplasty and noted a better patency, 79%, in claudicants [44]. Less favorable results are achieved in long stenoses, external iliac stenoses, and tandem lesions [45]. It is important to note that the majority of these studies are retrospective and in the earlier ones the patency rates have generally been expressed as a percentage of technically successful procedures rather than of all PTAs attempted.

The reported technical and initial clinical success of balloon angioplasty in iliac artery occlusions ranges between 78 and 98% and the 3-year patency rates range between 48% and 85% (Table 2).

Stenting of the iliac arteries represents a durable and curative treatment, with a 3-year patency rate of 41%–92% for stenoses and a 3-year patency rate of 64%–85% and 4-year patency rate of 54%–78% for occlusions (Tables 3 and 4). Murphy et al. [67] recently reported a primary patency rate of 74%, 8 years after stent placement, and Schurmann et al. treated 126 iliac lesions (66 stenoses and 60 occlusions) and reported a 10-year patency rate of 46% [32].

Stents do seem to improve the results of iliac angioplasty without increasing the complication rate. A meta-analysis by Bosch and Hunink, who compared the results of aorto-iliac PTA versus stenting in 2116 patients since

1989, demonstrated that stenting of iliac artery stenoses contributed to a relative risk reduction of 39% compared to balloon angioplasty, with respect to long-term patency, whereas complication rates and 30-day mortality rates did not differ significantly [68]. In a prospective randomized multicenter (>300 patients) trial comparing primary stenting and balloon angioplasty, the 5-year patency rate was 90% for stenting versus 68% for balloon angioplasty [69]. In contrast, primary stenting policy did not prove to be justified in another prospective randomized multicenter study which concluded that balloon angioplasty with selective stenting has an outcome similar to that with primary stenting, with comparable 2-year patency rates of 77% and 78%, respectively; however, 43% of the patients in the balloon-only treatment group were stented due to unsatisfactory angioplasty results [56]. The 5-year outcomes of the groups were also similar, with 82% and 80% of the treated iliac segments remaining free of the need for new revascularization procedures after a mean follow-up of 5.6 ± 1.3 years [70].

Factors stated to affect the patency of aorto-iliac endovascular interventions in a negative way include poor quality of runoff vessels, severity of ischemia, and extended length of diseased segments. It may have been suggested in the literature that location of the lesion at the external iliac artery adversely affects both primary and assisted-primary patency [71], but this has not been a uniform finding [72]. Female gender has also been associated with lower patency rates of the external iliac artery stents [73].

There has not been enough scientific evidence to prove the superiority of a specific stent type over the rest regarding immediate and/or long-term success. In a recent multicenter prospective randomized trial, comparison between two different self-expanding stents for the treatment of iliac artery obstructive lesions showed similar 1-year primary patency, complication, and symptomatic improvement rates [74].

Complications

Complication rates following PTA or stent placement in iliac arteries are shown in Tables 1–4. Major complications are defined as those that require therapy and hospitalization (not including overnight admission for observation only) or cause permanent adverse sequelae including death [26]. Pooled data are presented in Tables 5 and 6. Several patient factors such as obesity and cardiac and renal comorbidities contribute to increased complication rates [77].

The most frequent complication is hemorrhage from the access site (2.9%) resulting in a groin hematoma, although a retroperitoneal, properitoneal, or intraperitoneal hemor-

Table 1 PTA in iliac artery stenoses [37–43]: range

Patients	Claudicants	Technical and initial clinical success	Primary patency (5 yr)	Complications ^a
31–584	59%–91%	88%–99%	54%–92%	2.3%–13.4%

^a Including major or “significant” complications, as far as distinguished in the text

Table 2 PTA in iliac artery occlusions [11, 42^a, 46^b, 47, 48^b]: range

Patients	Claudicants	Technical and initial clinical success	Primary patency (3 yr)	Complications ^c
42–82	64%–91%	78%–98%	48%–85%	3.1%–10.6%

^a Patency rates based on an intention-to-treat analysis

^b Initial failure rate not included in the analysis

^c Including major or “significant” complications, as far as distinguished in the text

Table 3 Stents in iliac artery stenoses [11, 28, 49–58]: range

Patients	Claudicants	Technical and initial clinical success	Primary patency (3 yr)	Complications ^a
37–486	50%–100%	91%–100%	41%–92%	0–18 %

^a Including major or “significant” complications, as far as distinguished in the text

Table 4 Stents in iliac artery occlusions [12, 59–66]: range

Patients	Claudicants	Technical and initial clinical success	Primary patency	Complications ^a
59–212	40.5%–87%	81%–97%	3 yr: 64%–85% 4 yr: 59%–78%	1.4%–15%

^a Including major or “significant” complications, as far as distinguished in the text

Table 5 Complications: iliac PTA [43^a, 75^a]

Procedures	Major complications	Requiring surgery	Mortality
6,676	2.7%	1.2%	0.2 %

^a Pooled data from 38 studies

Table 6 Complications: iliac stenting [76^a]

Patients	Major complications	Requiring surgery	Mortality
1,948	6%	1.8%	0.4%

^a Pooled data from 18 studies

rhage may occasionally be met. In the suspicion of intra-abdominal hemorrhage, a prompt pelvic CT scan is mandatory, since early diagnosis will enable prompt subsequent treatment to prevent unfavorable systemic events, such as myocardial infarction, acute tubular necrosis, and even death. Pseudoaneurysm formation at the site of the arte-

rial puncture is less common (0.5%), with the treatment of choice for pseudoaneurysms >2 cm in diameter being percutaneous thrombin injection under ultrasound guidance.

Distal embolization occurs in 1.6% of iliac PTA/stenting procedures. Antegrade percutaneous catheter aspiration should be the treatment of choice for calf vessel embolus causing discontinuation of runoff. For larger emboli, such as those in the profunda femoris or common femoral arteries, surgical embolectomy is often required, as these emboli often contain plaque, not amenable to transcatheter aspiration or CDT.

Arterial rupture may complicate the procedure in 0.3% of cases. A patient complaining of persisting pain after balloon deflation prompts contrast administration in order to detect extravasation at the rupture site. Hypotension occurs quite often, usually due to vagal reaction and not volume depletion. Tamponade of the bleeding site with an angioplasty or occlusion balloon should be performed immediately and the placement of a covered stent should be considered. In case of failure, surgical treatment is required.

Although rare, stent infection has been increasingly encountered during the last 12 years [78–81]. This complication presents within 10–14 days after stent placement and clinical manifestations include fever, leukocytosis, bacteremia with positive blood cultures, hemodynamic instability, localized pain and/or mass, petechiae in the affected extremity, loss of pulse with symptoms of ischemia, and septic arthritis. Due to the devastating consequences of infection, some investigators advocate the administration of prophylactic antimicrobial agents, especially during long or repeated percutaneous access [82].

Summary

1. Endovascular therapy is the treatment of choice for type A lesions and the preferred treatment for type B lesions. In selective patients, comorbidities, the local interventionist’s experience, and patient preference may justify the application of this type of treatment in type C and even type D lesions.
2. Lesions can be accessed from the ipsilateral femoral, contralateral femoral, and brachial approach and both the intraluminal and the subintimal space can be used for successful recanalization.
3. The application of stents has improved the immediate hemodynamic and probably long-term clinical results of iliac PTA. However, the superiority of primary or direct stenting over selective stenting has not been proven yet.

4. The choice of stent type depends on lesion morphology and location, but otherwise there is insufficient evidence to support the use of a particular stent design. There is insufficient evidence to justify routine use of covered stents.
5. All patients should receive antiaggregant therapy following endovascular recanalization of iliac arteries. Unless subsequently contraindicated, this should be continued indefinitely.
6. There is no consensus regarding prophylaxis with antibiotics in iliac recanalization procedures

Appendix I: TASC Classification of Aorto-iliac Lesions [4]

Endovascular therapy is the treatment of choice for type A lesions and surgery is the treatment of choice for type D lesions. Endovascular treatment is the preferred treatment for type B lesions and surgery is the preferred treatment for good-risk patients with type C lesions. The patient's comorbidities, the fully informed patient preference, and the local operator's long-term success rates must be considered when making treatment recommendations for type B and type C lesions.

Appendix II: Definitions

According to the standards of the Society of Interventional Radiology, immediate technical success is defined as <30% final residual stenosis measured at the narrowest point of the vascular lumen and restoration of rapid antegrade flow on DSA [83]. Immediate clinical success is defined as improvement by at least one SVS/ISCVS category. Patients with tissue loss must improve by at least two categories and reach the level of claudication to be considered improved [84]. Clinical success during follow-up is defined as sustained improvement by at least one SVS/ISCVS category above the pretreatment clinical level.

Primary patency is defined as uninterrupted patency, with no procedures performed on or at the margins of the treated segment. Secondary or assisted primary patency is defined as patency following reintervention to restore patency of the treated segment due to restenosis or occlusion [59, 83, 84].

References

1. Kannel WB, Skinner JJ, Schwartz MJ, et al. (1970) Intermittent claudication: incidence in the Framingham study. *Circulation* 41:875–883
2. Newmann AB, Shemanski L, Manolio TA, et al. (1999) Ankle-arm index as a predictor of cardiovascular disease and mortality

Table A1 TASC classification of aorto-iliac lesions [4]

Type A lesions	Unilateral or bilateral stenoses of CIA Unilateral or bilateral, single, short (≤ 3 -cm) stenosis of EIA
Type B lesions	Short (≤ 3 -cm) stenosis of infrarenal aorta Unilateral CIA occlusion Single or multiple stenoses totaling 3–10 cm involving the EIA, not extending into the CFA Unilateral EIA occlusion not involving the origins of the internal iliac or CFA
Type C lesions	Bilateral CIA occlusions Bilateral EIA stenoses 3–10 cm long, not extending into the CFA Unilateral EIA stenosis extending into the CFA Unilateral EIA occlusion involving the origins of the internal iliac and/or CFA Heavily calcified unilateral EIA occlusion with or without involvement of origins of the internal iliac and/or CFA
Type D lesions	Infrarenal aorto-iliac occlusion Diffuse disease involving the aorta and both iliac arteries, requiring treatment Diffuse multiple stenoses involving the unilateral CIA, EIA, and CFA Unilateral occlusions of both the CIA and the EIA Bilateral occlusions of the EIA Iliac stenoses in patients with AAA requiring treatment and not amenable to endograft placement or other lesions requiring open aortic or iliac surgery

Note. CIA, common iliac artery; EIA, external iliac artery; CFA, common femoral artery; AAA, abdominal aortic aneurysm

- in the Cardiovascular Health Study. *Arterioscl Thromb Vasc Biol* 19:538–545
3. Diehm C, Schuster A, Allenberg JA, et al. (2004) High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients. A cross-sectional study. *Atherosclerosis* 172:195–205
 4. Norgren L, on behalf of the TASC Working Group (2007) The TransAtlantic Inter-Society Consensus (TASC II) document on management of peripheral arterial disease. *Eur J Vasc Endovasc Surg* 33 (Suppl 1):S1–S70
 5. Mc Lean GK, Cekirge S, Weiss JP, et al. (1994) Stent placement for iliac artery occlusions: modified “wire-loop” technique with use of the gooseneck loop snare. *J Vasc Interv Radiol* 5:701–703
 6. Jacobs DL, Motaganahalli RL, Cox DE, et al. (2006) True lumen re-entry devices facilitate subintimal angioplasty and stenting of total chronic occlusions: initial report. *J Vasc Surg* 43:1291–1296
 7. Murphy TP, Marks MJ, Webb MS (1997) Technical note: use of a curved needle for true lumen re-entry during subintimal iliac artery revascularization. *J Vasc Interv Radiol* 8:633–636
 8. McNamara TO, Fischer JR (1985) Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. *AJR* 144:769–775
 9. Shortell CK, Ouriel K (1994) Thrombolysis in acute peripheral arterial occlusion: predictors of immediate success. *Ann Vasc Surg* 8:59
 10. Sapoval MR, Chattelier G, Long AL, et al. (1996) Self-expandable stents for the treatment of iliac artery obstructive lesions: long term success and prognostic factors. *AJR* 166:1173–1179
 11. Long AL, Sapoval MR, Beyssen BM, et al. (1995) Strecker stent implantation in iliac arteries: patency and predictive factors for long-term success. *Radiology* 194:739–744
 12. Reyes R, Maynar M, Lopera J, et al. (1997) Treatment of chronic iliac artery occlusion with guidewire recanalization and primary stent placement. *J Vasc Interv Radiol* 8:1049–1055
 13. Blum U, Gabelmann A, Redecker M, et al. (1993) Percutaneous recanalization of iliac artery occlusions: results of a prospective study. *Radiology* 189:536–540
 14. Zana K, Otal P, Fornet B, et al. (2001) In vitro evaluation of a new rotational thrombectomy device: the Straub Rotarex catheter. *Cardiovasc Interv Radiol* 24:319–323
 15. Zeller T, Frank U, Burgelin K, et al. (2002) Long-term results after recanalization of acute and subacute thrombotic occlusions of the infra-aortic arteries and bypass-grafts using a rotational thrombectomy device. *Rofo* 174(12):1559–1565
 16. Murphy KD, Encarcacion CE, Le VA, Palmaz JC (1995) Iliac artery stent placement with the Palmaz stent: follow-up study. *J Vasc Interv Radiol* 6:312–329
 17. Brewster DC, Waltmann AC, O’Hara PJ, et al. (1979) Femoral arterial pressure measurements during aortography. *Circulation* 60:120–124
 18. Onal B, Erhan TI, Yucel C, et al. (1998) Primary stenting for complex atherosclerotic plaques in aortic and iliac stenoses. *Cardiovasc Interv Radiol* 21:386–392
 19. Dyett JF, Watts WG, Ettles DF, et al. (2000) Mechanical properties of metallic stents: How do these properties influence the choice of stent for specific lesions? *Cardiovasc Interv Radiol* 23:47–54
 20. Leung DA, Spinosa DJ, Hagspiel KD, et al. (2003) Selection of stents for treating iliac arterial occlusive disease. *J Vasc Interv Radiol* 14:137–152
 21. Schurmann K, Vorwerk D, Uppenkamp D, et al. (1997) Iliac arteries: plain and heparin-coated Dacron-covered stents compared with non-covered metal stents: an experimental study. *Radiology* 203:55
 22. Rzcudlo EM, Powell RJ, Zwolak RM, et al. (2003) Early results of stent-grafting to treat diffuse aortoiliac occlusive disease. *J Vasc Surg* 7:1175–1180
 23. Lammer J, Dake MD, Bleyen J, et al. (2000) Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. *Radiology* 217:95–104
 24. Vorwerk D, Gunther RW (2001) Percutaneous interventions for treatment of iliac artery stenoses and occlusions. *World J Surg* 25:319–327
 25. Hamer OW, Borisch I, Finkenzeller T, et al. (2004) Iliac artery stent placement: clinical experience and short-term follow-up regarding a self-expanding nitinol stent. *J Vasc Interv Radiol* 15:1231–1238
 26. Balzer JO, Gastinger V, Ritter R, et al. (2006) Percutaneous interventional reconstitution of the iliac arteries: primary and long-term success rate in selected TASC A and D lesions. *Eur Radiol* 16:124–131
 27. Strecker EP, Boos IL, Hagen B (1996) Flexible tantalum stents for the treatment of iliac artery lesions: long term patency, complications and risk factors. *Radiology* 199:641–647
 28. Kudo T, Chandra FA, Ahn SS (2005) Long-term outcomes and predictors of iliac angioplasty with selective stenting. *J Vasc Surg* 42:466–475
 29. Uberoi R, Sarkar B, Coleman J, et al. (2002) Duplex follow up of aorto-iliac stents. *Eur J Vasc Endovasc Surg* 23(4):331–335
 30. Jacobs TF, Wintersperger BJ, Becker CR (2004) MDCT-imaging of peripheral arterial disease. *Semin Ultrasound CT MR* 25(2):145–155
 31. Maintz D, Kugel H, Schellhammer F, et al. (2001) In vitro evaluation of intravascular stent artifacts in three-dimensional MR angiography. *Invest Radiol* 36:218–224
 32. Schurmann K, Mahnken A, Meyer J, et al. (2002) Long-term results 10 years after iliac artery stent placement. *Radiology* 224:731–738
 33. Di Mario C, Marsico F, Adamian M, et al. (2000) New recipes for in-stent restenosis: Cut, grade, roast, or sandwich the neointima? *Heart* 84:471–475
 34. Ettles DF, MacDonald AW, Burgess AA, et al. (1998) Directional atherectomy in iliac stent failure: clinical technique and histopathologic correlation. *Cardiovasc Interv Radiol* 21:475–480
 35. Kawamata H, Kumazaki T, Tajima H, Niggemann P (2002) Peripheral directional atherectomy evaluated with a rotational digital angiography system. *J Nippon Med Sch* 67(5):335–341
 36. Tsetis D, Morgan R, Belli AM (2006) Cutting balloons for the treatment of vascular stenoses. *Eur Radiol* 16:1675–1683
 37. van Andel GJ, van Erp WF, Krepel VM, et al. (1985) Percutaneous transluminal dilatation of the iliac artery: long-term results. *Radiology* 156:321–324
 38. Blankensteijn JD, van Broonhoven TJ, Lampmann L (1986) Role of percutaneous transluminal angioplasty in aorto-iliac reconstruction. *J Cardiovasc Surg* 27:466–468
 39. Jeans WD, Armstrong S, Cole SEA, et al. (1990) Fate of patients undergoing transluminal angioplasty for lower-limb ischemia. *Radiology* 177:559–564
 40. Tegtmeier CJ, Hartwell GD, Selby JB, et al. (1991) Results and complications of angioplasty in aortoiliac disease. *Circulation* 83 (Suppl I):I-53–I-60
 41. Jorgensen B, Skovgaard N, Norgard J, et al. (1992) Percutaneous transluminal angioplasty in 226 iliac artery stenoses: role of the superficial femoral artery for clinical success. *Vasa* 21:382–386
 42. Johnston KW (1993) Iliac arteries: reanalysis of results of balloon angioplasty. *Radiology* 186:207–212
 43. Rholl KS (1997) Percutaneous aortoiliac intervention in vascular disease In: Baum S, Pentecost MJ (eds) *Abram’s angiography:*

- Vol III. Interventional radiology. Little, Brown, Boston, pp 225–261
44. Becker GJ, Katzen BT, Dake MD (1989) Non-coronary angioplasty. *Radiology* 170:921–940
 45. Johnston KW, Rae M, Hogg-Johnston SA, et al. (1987) Five-year results of a prospective study of percutaneous transluminal angioplasty. *Ann Surg* 206:403–413
 46. Colapinto RF, Stronell RD, Johnston WK (1986) Transluminal angioplasty of complete iliac obstructions. *AJR* 146:859–862
 47. Hausegger KA, Lammer J, Klein GE, et al. (1991) Percutaneous recanalization of pelvic artery occlusions: fibrinolysis, PTA, stents. *Rofo* 155:550–555
 48. Gupta AK, Ravimandalam K, Rao VR, et al. (1993) Total occlusion of iliac arteries: results of balloon angioplasty. *Cardiovasc Interv Radiol* 16:165–177
 49. Palmaz JC, Laborde JC, Rivera FJ, et al. (1992) Stenting of iliac arteries with the Palmaz stent: experience from a multicentric trial. *Cardiovasc Interv Radiol* 15:291–297
 50. Vorwerk D, Gunther RW (1992) Stent placement in iliac arterial lesions: three years of clinical experience with the Wallstent. *Cardiovasc Interv Radiol* 15:285–290
 51. Streckler EP, Hagen P, Liermann D, et al. (1993) Iliac and femoropopliteal vascular occlusive disease treated with flexible tantalum stents. *Cardiovasc Interv Radiol* 16:158–164
 52. Wolf YG, Schatz RA, Knowles HJ, et al. (1993) Initial experience with the Palmaz stent for aortoiliac stenoses. *Ann Vasc Surg* 7:254–261
 53. Martin EC, Katzen BT, Benenati JF, et al. (1995) Multicenter trial of the Wallstent in iliac and femoral arteries. *J Vasc Interv Radiol* 6:843–849
 54. Vorwerk D, Guenther R, Schurmann K, et al. (1996) Aortic and iliac stenoses: follow-up results of stent placement after insufficient balloon angioplasty in 118 cases. *Radiology* 198:45–48
 55. Murphy TP, Webb MS, Lambiasi RE, et al. (1996) Percutaneous revascularization of complex iliac artery stenoses and occlusions with use of Wallstent: three-year experience. *J Vasc Interv Radiol* 7:21–27
 56. Tetteroo E, van der Graaf Y, Bosch JL, et al. (1998) Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. The Dutch Iliac Stent Trial Study Group. *Lancet* 351:1153–1159
 57. Treiman GS, Schneider PA, Lawrence PF, et al. (1998) Does stent placement improve the results of ineffective or complicated iliac artery angioplasty? *J Vasc Surg* 28:104–112
 58. Hassen -Khodja R, Sala F, Declémy S, et al. (2001) Value of stent placement during percutaneous transluminal angioplasty of the iliac arteries. *J Cardiovasc Surg (Torino)* 42:369–374
 59. Vorwerk D, Guenther R, Schurmann K, et al. (1995) Primary stent placement for chronic iliac artery occlusions: follow-up results in 103 patients. *Radiology* 194:745–749
 60. Dyett JF, Gaines PA, Nicholson AA, Cleveland T, et al. (1997) Treatment of chronic iliac artery occlusions by means of endovascular stent placement. *J Vasc Interv Radiol* 8:394–353
 61. Henry M, Amor M, Ethevenot G, et al. (1998) Percutaneous treatment of iliac occlusions: long-term follow-up in 105 patients. *J Endovasc Surg* 5:228–235
 62. Ballard JL, Bergan JJ, Singh P, et al. (1998) Aortoiliac stent deployment versus surgical reconstruction: analysis of outcome and cost. *J Vasc Surg* 28:94–101
 63. Scheinert D, Schroder M, Ludwig J, et al. (2001) Stent-supported recanalization of chronic iliac occlusions. *Am J Med* 110:708–715
 64. Uher P, Nyman U, Lindh M, et al. (2002) Long-term results for stenting chronic iliac occlusions. *J Endovasc Ther* 9:67–75
 65. Funovics MA, Lackner B, Cejna M, et al. (2002) Predictors of long-term results after treatment of iliac artery obliteration by transluminal angioplasty and stent placement. *Cardiovasc Interv Radiol* 25:397–402
 66. Carnevale FC, De Blas M, Merino S, et al. (2004) Percutaneous endovascular treatment of chronic iliac artery occlusion. *Cardiovasc Interv Radiol* 27:447–452
 67. Murphy TP, Ariatnam NS, Carney WI, et al. (2004) Aortoiliac insufficiency: long-term experience with stent placement for treatment. *Radiology* 231:243–249
 68. Bosch JL, Hunink MGM (1997) Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. *Radiology* 204:87–96
 69. Richter GM, Roeren T, Brado M, et al. (1995) Arterial stenting: randomized trial between primary iliac stenting vs PTA in iliac artery stenosis abd obstruction. *Eur Radiol* 5:103
 70. Klein WM, van der Graaf Y, Seegers J, et al. (2004) Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease. The Dutch Iliac Study. *Radiology* 232:491–498
 71. Powell RJ, Fillinger M, Walsh DB, et al. (2000) Predicting outcome of angioplasty and selective stenting of multisegment iliac artery occlusive disease. *J Vasc Surg* 32:564–569
 72. Lee ES, Steenson CC, Trimble KE, et al. (2000) Comparing patency rates between external iliac and common iliac artery stents. *J Vasc Surg* 31:889–894
 73. Timaran CH, Stevens SL, Freeman MB, et al. (2001) External iliac and common iliac artery angioplasty and stenting in men and women. *J Vasc Surg* 34:440–446
 74. Ponec D, Jaff MR, Swischuk J, et al. (2004) The Nitinol Smart stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US Trial results. *J Vasc Interv Radiol* 15:911–918
 75. Rholl K, Van Breda A (1994) Percutaneous intervention for aortoiliac disease. In: Strandness E, Van Breda A (eds) *Vascular diseases*. Churchill Livingstone, New York, pp 433–466
 76. Murphy TP, Khwaja AA, Webb MS (1998) Aortoiliac stent placement in patients treated for intermittent claudication. *J Vasc Interv Radiol* 9:421–428
 77. TransAtlantic Inter-Society Consensus Working Group (2000) Management of peripheral arterial disease. *J Vasc Surg* 31:97–121
 78. Weinberg DJ, Cronin DW, Baker AG (1996) Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and Palmaz stent insertion: a case report and literature review. *J Vasc Surg* 162–166
 79. McIntyre KE, Walser E, Hagman J, et al. (1997) Mycotic aneurysm of the common iliac artery and distal aorta following stent placement. *Vasc Surg* 31:551–557
 80. Hoffman AI, Murphy TP (1997) Septic arteritis causing iliac artery rupture and aneurismal transformation of the distal aorta after iliac stent placement. *J Vasc Interv Radiol* 8:215–219
 81. Bunt TJ, Gill HK, Smith DC, et al. (1997) Infection of a chronically implanted iliac artery stent. *Ann Vasc Surg* 11:529–532
 82. Paget DS, Bukhari RH, Zayyat EJ, et al. (1999) Infectability of endovascular stents following antibiotic prophylaxis or after arterial wall incorporation. *Am J Surg* 178:219–224
 83. Sacks D, Marinelli DL, Martin LG, et al. (2003) Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. *J Vasc Interv Radiol* 14:S395–S404
 84. Rutherford RB, Baker JD, Ernst CB, et al. (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg* 26:517–538